The U.S. government could cripple the biofuel sector if it decides to include indirect land-use change in formulas that calculate and compare the amount of biofuel-related greenhouse gases with emissions from petroleum abroad, representatives from Growth Energy and two other trade groups said at a House committee hearing. The use of ILUC formulas "will cap domestic ethanol production," said Tom Buis of Growth Energy.
Johnson & Johnson announced that it is taking over Cougar Biotechnology in a deal worth about $970 million to bolster its oncology business. The acquisition, which is expected to close in the third quarter, will grant J&J rights to abiraterone acetate, an experimental cancer treatment in two pivotal stage trials.
Cellceutix Pharma applied for a U.S. patent to cover formulations of its cancer compound Kevetrin and other agents that have similar structures to Kevetrin. The company plans to submit a patent application in other countries within a year of the U.S. filing.
Human Genome Sciences submitted for FDA approval its monoclonal antibody drug ABthrax as a treatment for inhalation anthrax. ABthrax, also known as raxibacumab, was found to improve survival in animal tests and safety studies on healthy human volunteers.
Researchers hope compounds called necrostatins will pave the way for drugs that treat diseases and injuries in which cell death plays a key role. Rights to the compounds were acquired from Harvard University by TetraLogic Pharmaceuticals, which plans to file the product for FDA approval next year.